To assess the effectiveness of medical treatment for metastatic breast cancer.
Two people independently reviewed the trials to determine whether they met the inclusion criteria and discussed disagreements about rejection between themselves. When disagreements could not be resolved, a third independent reviewer's opinion was sought.
Assessment of study quality
The authors used only the criteria that a study was of acceptable quality if it was an RCT design. There was no formal assessment of the methodology of the RCTs.
Data extraction
Two of the authors read the papers to extract the data. Agreement between the two authors was assessed comparing 246 time points from 19 randomly selected different survival curves, which were read by both the investigators. The mean difference between measurements by the two readers was 0.83 percentage points (95% CI: 0.69, 0.96).
Data extracted included: year of publication; time period of patient accrual, number of eligible patients randomised, median age of patients; menopausal status; state of estrogen receptors; clinical patterns of relapse; prior palliative therapies; full description of treatment regimens used; presence of any health-related quality-of-life assessment, and outcome measures.
Methods of synthesis
How were the studies combined? A fixed-effect model was used to pool the studies using the Peto method for response rates and adverse effects, and the log HRs were combined across trials using an inverse variance weighting.
How were differences between studies investigated?
Predefined subsets of studies were formed and summarised and the chi-square statistic was used to test for heterogeneity between the trials.
Results of the review
A total of 189 trials met the inclusion criteria with 31,150 participants.
Heterogeneity was not found for comparisons 1, 3, 4, 5, 6, 7, 8, 10, 11 and 12 ; but was found for interventions 2 and 9. Statistically significant differences for response emerged for comparisons 1, 2, 3, 5, 7, 8, 11, and 12 Quality of life was measured in only 2,995 of 31,510 patients (9.5%).
